logo
Treating cold sores with anti-virals ‘may slash risk of developing Alzheimer's'

Treating cold sores with anti-virals ‘may slash risk of developing Alzheimer's'

Treating cold sores with anti-viral medicines could help slash the risk of Alzheimer's disease, research suggests.
Previous studies have found that the herpes simplex virus type 1 (HSV-1) can lie dormant in human cells for a lifetime before 're-awakening', leading to dementia symptoms.
Experts have discovered that HSV-1 causes changes that resemble those in the brains of dementia patients, such as amyloid plaque-like formations and inflammation.
Now, a large US study suggests that treating HSV-1 may be a route to lessening the risk of Alzheimer's disease.
Researchers, including from pharmaceutical firm Gilead Sciences and the University of Washington in Seattle, used data on 344,628 people with Alzheimer's matched with the same number of people without the disease.
All were aged over 50 and the diagnosis of Alzheimer's was made between 2006 and 2021.
A history of HSV-1 diagnosis was noted for 1,507 (0.44%) patients with Alzheimer's, compared with 823 (0.24%) of those without.
Nearly two thirds (65%) of those with Alzheimer's disease were women, with an average age if 73.
The study found that people who had suffered the herpes virus had an 80% increased risk of Alzheimer's, even when other factors were taken into account.
But those with HSV-1 who used anti-virals to treat the virus were 17% less likely to develop Alzheimer's compared with those who did not the medicines.
Among the 2,330 people with a history of HSV-1 infection, 931 (40%) used anti-virals after their diagnosis.
The authors, writing in the journal BMJ Open, concluded: 'Findings from this large…study implicate HSV-1 in the development of Alzheimer's disease and highlight anti-herpetic therapies as potentially protective for Alzheimer's and related dementia.'
In the UK, the drug aciclovir is one of those available for treating cold sores, chickenpox, shingles and other herpes virus infections.
The researchers also looked at the potential role of other herpes viruses, including HSV-2, varicella zoster virus (which causes chickenpox), and cytomegalovirus.
Both HSV-2 and varicella zoster virus infections were also associated with a heightened risk of Alzheimer's disease.
Exactly how HSV-1 and other viruses might heighten the risk of dementia is not clear, point out the researchers.
'However, studies have shown that inflammatory alterations in the brain caused by HSV infection are pivotal in (Alzheimer's disease) development,' they added.
HSV-1 DNA is also found in the plaques characteristic of Alzheimer's disease, and people carrying the most common genetic risk factor for the disease are more susceptible to HSV infections, they said.
Professor Tara Spires-Jones, from the University of Edinburgh, said: 'This is a well-conducted study adding to strong data in the field linking HSV-1 and other viral infections to increased risk of developing Alzheimer's disease, but it is important to note that HSV-1 infection, which is extremely common in the population, is by no means a guarantee that someone will develop Alzheimer's.
'Why viral infections may increase risk of dementia is not fully understood, but the most likely explanation is that infections increase inflammation in the body and contribute to age-related brain inflammation.
'More research is needed to understand the best way to protect our brains from Alzheimer's disease as we age, including a better understanding of links between viral infection and Alzheimer's risk.'
Dr David Vickers, from the University of Calgary in Canada, said the 'research exaggerates the role of HSV-1, failing to appreciate its absence in 99.56% of Alzheimer's disease cases'.
He added: 'The observed 17% hazard reduction with anti-herpetic drugs translates to a mere nine-month delay in Alzheimer's disease onset.'
Dr Richard Oakley, director of research and innovation at the Alzheimer's Society, said: 'Results from this observational study suggested that people with recorded cold sore infections were more likely to develop Alzheimer's disease, and interestingly those prescribed antiviral drugs had a slightly lower risk.
'But this doesn't prove that cold sores cause Alzheimer's disease, or that anti-virals prevent it.
'The data came from insurance records, often based on self-reported symptoms which may miss or misclassify infections, and didn't track how often people had cold sores or how consistently they took medication.
'Much more research is needed to explore exactly how viruses might be involved and before we can draw firm conclusions.'
Dr Sheona Scales, director of research at Alzheimer's Research UK, welcomed the study but said more research was needed.
'We know there are 14 established risk factors for dementia, and there's not enough evidence to include infections in this list.
'This study doesn't tell us if infections are causing the risk, it only shows an association. Further research is needed to understand what the underlying biology around this is.'
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Fat jabs reduce the risk of cancer by 17% in overweight and obese people – except one, warn scientists
Fat jabs reduce the risk of cancer by 17% in overweight and obese people – except one, warn scientists

Scottish Sun

time8 hours ago

  • Scottish Sun

Fat jabs reduce the risk of cancer by 17% in overweight and obese people – except one, warn scientists

Click to share on X/Twitter (Opens in new window) Click to share on Facebook (Opens in new window) WEIGHT loss jabs could lower the risk of cancer, scientists say. They found GLP-1s like Ozempic and Mounjaro reduced the overall chances of the disease by 17 per cent in overweight and obese patients. Sign up for Scottish Sun newsletter Sign up 2 Medication like Mounjaro could help people lose weight and lower their risk of cancer Credit: Getty The decreased risk was strongest for ovarian, womb and certain brain tumours. But people taking the jabs were still less likely to develop other types, including pancreatic, bladder and breast cancer, than those not on the medication. It's another breakthrough for the 'miracle' injections, which have already been shown to tackle type 2 diabetes, heart disease, stroke and possibly dementia. Author Dr Jiang Bian, from the Indiana University School of Medicine, said: 'GLP-1s are widely prescribed for glycemic control in type 2 diabetes and have recently gained popularity for weight management. 'We found they were associated with a reduced overall risk of cancer. 'Even modest changes in cancer risk could have substantial public health implications.' However, researchers also found that taking so-called 'fat jabs', which mimic a hormone to make users feel full, might be associated with an increased risk of kidney cancer, especially among users under 65. 'Further research is needed to clarify this potential risk,' Dr Bian said. The study, published in the journal JAMA Oncology, couldn't conclude whether the change in cancer risk over eight years was due to the jabs themselves or drug-induced weight loss. But scientists reckon that lower body fat, improved insulin sensitivity and reduced inflammation could be to thank. Don't fall for fake Mounjaro scams to save money on fat jab - it put me in a 'coma' & I'm still suffering, says Aisleyne Horgan-Wallace In trials, semaglutide (sold as Ozempic and Wegovy) helped users lose around 15 per cent of their body weight in 68 weeks, while those on tirzepatide (Mounjaro) shed up to 21 per cent. Dr Stephen Lawrence, associate clinical professor at the University of Warwick, who was not involved in the study, said: 'These drugs not only help shed pounds and lower blood sugar, but might add a modest bonus by being slightly associated with reducing overall cancer risk, especially for specific women's cancers. 'With millions now eligible for GLP-1 therapy, even small shifts in risk matter at scale. 'These medicines remain widely safe, with a reassuring cancer profile and only a whisper of concern about an associated increase in kidney cancer.' 2

Gilead unit to acquire cell therapy developer Interius for $350 million
Gilead unit to acquire cell therapy developer Interius for $350 million

Reuters

time9 hours ago

  • Reuters

Gilead unit to acquire cell therapy developer Interius for $350 million

Aug 21 (Reuters) - Gilead Sciences' (GILD.O), opens new tab unit Kite Pharma said on Thursday it will acquire privately-held biotech firm Interius BioTherapeutics for $350 million in cash to advance CAR T-cell cancer therapies that are delivered directly into patients. The acquisition will enable Kite to use Interius' platform to deliver cell therapy directly into patients, simplifying treatment processes and reducing costs, the company said. Kite said the deal, expected to close pending regulatory approvals, will reduce Gilead's 2025 profit per share by about 23 cents to 25 cents. In CAR T-cell therapy, a patient's T-cells, a key part of the immune system, are modified to better recognize and attack cancer cells. Traditional CAR T-cell therapies, including Kite's approved blood cancer treatments Yescarta and Tecartus, involve taking immune cells from a patient. These are modified in a lab, and then put back into the patient's body - a process that is both complex and expensive. Interius' so-called "in-vivo" approach uses intravenous infusion to deliver DNA directly into cells, potentially accelerating and simplifying treatments, according to the Kite. Interest in in-vivo CAR T-cell platforms has surged, with over $2 billion invested and multiple partnerships formed recently, according to a report by clinical research firm Novotech. The report noted that more than five in-vivo CAR T-cell programs have entered clinical trials, and disclosed assets are expected to surpass 100 by the end of 2025. After the deal is approved, Interius' operations will merge with Kite's research team in Philadelphia, the Gilead unit added.

The nifty injection trick to BOOST weight loss on fat jabs – and 6 ‘simple' mistakes to avoid
The nifty injection trick to BOOST weight loss on fat jabs – and 6 ‘simple' mistakes to avoid

Scottish Sun

time10 hours ago

  • Scottish Sun

The nifty injection trick to BOOST weight loss on fat jabs – and 6 ‘simple' mistakes to avoid

FOR millions around the world, fat jabs like Mounjaro and Wegovy have been a godsend for a simple and stress-free way to shed those stubborn pounds. But if you want to make the most of them, you need to be injecting the most effective way, and that's not all... there are several mistakes you could be making that might be getting in the way of a slimmer you. 5 If you're failing to see results, it could be down to using the pen incorrectly For some users, the GLP-1 weight loss jabs are not proving to be the fat-busting gift they were led to...

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store